The National Institute of Allergy and Infectious Diseases (NIAID, ) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services. NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases. NIAID has on-campus laboratories in Maryland and Hamilton, Montana, and funds research conducted by scientists at institutions in the United States and throughout the world. NIAID also works closely with partners in academia, industry, government, and non-governmental organizations in multifaceted and multidisciplinary efforts to address emerging health challenges such as the H1N1/09 pandemic and the COVID-19 pandemic.
History
NIAID traces its origins to a small laboratory established in 1887 at the Marine Hospital on Staten Island, New York (now Bayley Seton Hospital). Officials of the Marine Hospital Service in New York decided to open a research laboratory to study the link between microscopic organisms and infectious diseases. Joseph J. Kinyoun, a medical officer with the Marine Hospital Service, was selected to create this laboratory, which he called a "laboratory of hygiene". Kinyoun's lab was renamed the Hygienic Laboratory in 1891 and moved to Washington, D.C., where Congress authorized it to investigate "infectious and contagious diseases and matters pertaining to the public health." With the passage of the Ransdell Act in 1930, the Hygienic Laboratory became the National Institute of Health. In 1937, the Rocky Mountain Laboratory, then part of the United States Public Health Service, was transferred to Division of Infectious Diseases, part of the NIH. In mid-1948, the National Institute of Health became the National Institutes of Health (NIH) with the creation of four new institutes. On October 8, 1948, the Rocky Mountain Laboratory and the Biologics Control Laboratory were joined with the NIH Division of Infectious Diseases and Division of Tropical Diseases to form the National Microbiological Institute. In 1955, Congress changed the name of the National Microbiological Institute to the National Institute of Allergy and Infectious Diseases to reflect the inclusion of allergy and immunology research. That change became effective on December 29, 1955. On April 30, 2025, Secretary of Health and Human Services Robert F. Kennedy Jr. ordered all research stopped at the lab amidst similar cuts to health programs in the United States.
List of directors The following have been directors of the National Institute of Allergy and Infectious Diseases:
Organizational structure
NIAID is composed of the Office of the Director (OD), four extramural divisions:
Division of Acquired Immunodeficiency Syndrome (DAIDS) Division of Allergy, Immunology, and Transplantation (DAIT) Division of Microbiology and Infectious Diseases (DMID) Division of Extramural Activities (DEA) and three intramural divisions:
Division of Clinical Research (DCR) Division of Intramural Research (DIR) Vaccine Research Center (VRC) The Dale and Betty Bumpers Vaccine Research Center is composed of four laboratories and two programs:
Immunology Laboratory Viral Pathogenesis Laboratory Virology Laboratory Vaccine Production Program Laboratory Clinical Trials Program Translational Research Program
Research priorities
NIAID's research priorities are focused on:
"expanding the breadth and depth of knowledge in all areas of infectious, immunologic, and allergic diseases" "developing flexible domestic and international research capacities to respond appropriately to emerging and re-emerging disease threats wherever they may occur." NIAID's mission areas are:
Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) The goals in this area are finding a cure for HIV-infected individuals; developing preventive strategies, including vaccines and treatment as prevention; developing therapeutic strategies for preventing and treating co-infections such as TB and hepatitis C in HIV-infected individuals; and addressing the long-term consequences of HIV treatment. Biodefense and Emerging Infectious Diseases (BioD) The goals of this mission area are to better understand how these deliberately emerging (i.e., intentionally caused) and naturally emerging infectious agents cause disease and how the immune system responds to them. Infectious and Immunologic Diseases (IID) The goal of this mission area is to understand how aberrant responses of the immune system play a critical role in the development of immune-related disorders such as asthma, allergies, autoimmune diseases, and transplant rejection. This research helps improve the understanding of how the immune system functions when it is healthy or unhealthy and provides the basis for development of new diagnostic tools and interventions for immune-related diseases.
Achievements
… excerpt ends here. Continue reading the full article.






